Welcome to our dedicated page for Novartis news (Ticker: NVS), a resource for investors and traders seeking the latest updates and insights on Novartis stock.
Novartis AG (NVS) generates a steady flow of news driven by clinical milestones, regulatory decisions, strategic collaborations and financial updates across its innovative medicines portfolio. As a pharmaceutical preparation manufacturing company, Novartis regularly announces US Food and Drug Administration (FDA) approvals, late‑stage trial readouts and label changes that shape its position in immunology, cardiovascular disease, kidney disease, neuroscience and autoimmune disorders.
Recent news has highlighted multiple FDA approvals, including Rhapsido (remibrutinib), an oral Bruton's tyrosine kinase inhibitor for adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines; label expansion for Leqvio (inclisiran) enabling first‑line use as monotherapy with diet and exercise to reduce LDL‑C in adults with hypercholesterolemia; Vanrafia (atrasentan) for reduction of proteinuria in primary IgA nephropathy; and Fabhalta (iptacopan) as the first approved treatment for C3 glomerulopathy to reduce proteinuria. Novartis has also reported positive Phase III results for ianalumab in Sjögren’s disease and an FDA approval for Itvisma, a gene replacement therapy for spinal muscular atrophy in a broad age range.
In addition to product‑specific developments, Novartis news often covers strategic deals and pipeline expansion. Examples include agreements with Argo Biopharma for cardiovascular siRNA assets, a global license and collaboration with PTC Therapeutics for the PTC518 Huntington’s disease program, and a planned acquisition of Avidity Biosciences to strengthen its late‑stage neuroscience pipeline. The company also communicates on collaborations in radioligand therapies, such as its SSTR2‑targeting radiotherapeutic candidate partnership with Ratio Therapeutics.
Investors and followers of NVS news can expect coverage of earnings and financial reports via Form 6‑K filings, guidance updates on constant‑currency sales growth, and commentary on the expected impact of major transactions. For those tracking developments in specific diseases—such as chronic spontaneous urticaria, hidradenitis suppurativa, IgA nephropathy, C3 glomerulopathy, Sjögren’s disease, cardiovascular risk reduction and spinal muscular atrophy—the Novartis news flow provides insight into late‑stage data, regulatory timelines and commercial positioning. Bookmarking the Novartis news page on Stock Titan can help users monitor these ongoing clinical, regulatory and strategic updates.
Summary not available.
Summary not available.
Novartis presented new data for Piqray (alpelisib) at the San Antonio Breast Cancer Symposium, demonstrating significant benefits in patients with HR+/HER2- metastatic breast cancer (mBC) and PIK3CA mutations. The BYLieve study showed a median overall survival of 26.4 months for patients treated with Piqray and fulvestrant after CDK4/6 inhibition. Approximately 48.7% of patients showed no disease progression at six months in the cohort treated after chemotherapy or endocrine therapy. No new safety signals were observed, confirming the drug's tolerability.
AavantiBio has appointed Dr. Jenny Marlowe as Chief Scientific Officer. She brings nearly 15 years of experience in the biopharmaceutical sector, previously serving at Bluebird Bio (NASDAQ: BLUE) as VP of Preclinical & Translational Development. Dr. Marlowe will lead scientific research and preclinical development at AavantiBio, which focuses on gene therapies for rare diseases. The company has secured over $107 million in Series A financing and is advancing its gene therapy pipeline, including partnerships with leading organizations such as the University of Florida.
On September 19, 2021, Novartis announced the final overall survival analysis of the Phase III MONALEESA-2 study for Kisqali (ribociclib) combined with letrozole in postmenopausal women with HR+/HER2- advanced breast cancer. The treatment showed a statistically significant median overall survival improvement (63.9 vs. 51.4 months) and a 12-month delay in chemotherapy initiation compared to letrozole alone. No new safety signals were reported. Novartis plans to submit these findings to health authorities for label updates, reinforcing Kisqali's position in advanced breast cancer treatment.
Ionis Pharmaceuticals announced significant progress for pelacarsen, a potential treatment for lipoprotein(a)-driven cardiovascular disease, as the Lp(a) HORIZON study reached 50% enrollment with 4,000 participants. This Phase 3 study aims to support the drug's indication for reducing cardiovascular risk. Ionis received a $25 million milestone payment from Novartis and is eligible for up to $675 million in additional milestones, along with mid-teens to low 20% royalties on pelacarsen sales. This investigational medicine utilizes LICA technology to target elevated Lp(a) levels, a significant risk factor for cardiovascular diseases.
On September 16, 2020, the Novartis US Foundation announced a USD 25 million commitment to tackle health inequities in underserved communities in the United States, particularly focusing on diversity in clinical trials. This funding is aimed at fostering partnerships and enhancing healthcare access amidst the ongoing challenges of the COVID-19 pandemic and racial disparities. Previously, the foundation had committed over USD 10 million to support healthcare systems in overcoming barriers to care. The foundation also seeks to address the underrepresentation of minorities in clinical trials.